Drug Profile


Alternative Names: INDI-702; NM-702; NT-702

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nissan Chemical Industries
  • Class Antiplatelets; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Thromboxane A2 synthase inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Asthma; Intermittent claudication

Most Recent Events

  • 12 May 2015 Nissan Chemical Industries terminates the license agreement with Taisho Pharmaceutical for parogrelil
  • 26 Aug 2009 Phase II development is still ongoing for intermittent claudication caused by arteriosclerosis obliterans in Japan
  • 26 Aug 2009 Discontinued - Phase II for intermittent claudication caused by spinal canal stenosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top